- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06514794
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed/Refractory Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-RRex)
The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a Phase 2, single-arm, multi-center, open label study in patients with R/R T-ALL/LBL and T-ALL/LBL in remission but remaining MRD positive.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Allotera Therapeutics Clinical Trials Clinical Trials
- Phone Number: 314-501-1968
- Email: clinicaltrials@alloteratx.com
Study Locations
-
-
Victoria
-
Melbourne, Victoria, Australia, 3000
- Recruiting
- Peter Mac Callum Cancer Institute
-
Contact:
- Ashish Bajel, M.D.
- Email: pcctu.haema@petermac.org
-
Contact:
- PCCTU HaemA
-
Principal Investigator:
- Ashish Bajel, M.D.
-
Melbourne, Victoria, Australia, 3000
- Recruiting
- Royal Children's Melbourne
-
Contact:
- Seong Lin Khaw, M.D.
- Email: clinicaltrialsmanager@rch.org.au
-
-
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope
-
Principal Investigator:
- Ibrahim Aldoss, MD
-
Contact:
- Email: tolaitan@coh.org
-
Los Angeles, California, United States, 90027
- Recruiting
- Children's Hospital Los Angeles
-
Principal Investigator:
- Deepa Bhojwani, MD
-
Contact:
- Amber Medina
- Phone Number: (323) 361-5654
- Email: ammedina@chla.usc.edu
-
Contact:
- Amneh Aljazzar
- Phone Number: 323-361-4156
- Email: aaljazzar@chla.usc.edu
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Recruiting
- Colorado Blood Cancer Institute
-
Principal Investigator:
- Alireza Eghtedar, M.D.
-
-
District of Columbia
-
Washington D.C., District of Columbia, United States, 20010
- Recruiting
- Children's National Hospital
-
Principal Investigator:
- Keri Toner, MD
-
Contact:
- Mallika Khanna
- Phone Number: 202-476-8938
- Email: mkhanna1@childrensnational.org
-
-
Florida
-
Tampa, Florida, United States, 33612
- Recruiting
- H. Lee Moffitt Cancer Center and Research Institute Hospital
-
Contact:
- Garrett Welch
- Email: Garrett.Welch@Moffitt.org
-
Principal Investigator:
- Rawan Faramand, M.D.
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- Recruiting
- Children's Hospital of Atlanta
-
Principal Investigator:
- Muna Qayed, MD
-
Contact:
- Judson Russell
- Phone Number: 404-433-6653
- Email: BMT@choa.org
-
-
Missouri
-
St Louis, Missouri, United States, 63108
- Recruiting
- Washington University Saint Louis
-
Contact:
- Katie Stricker
- Email: kstricker@wustl.edu
-
-
New York
-
New York, New York, United States, 10017
- Recruiting
- Memorial Sloan Kettering Cancer Center -- Pediatrics
-
Contact:
- Ramzi Khalaf
- Email: khalafr@mskcc.org
-
Principal Investigator:
- Kevin Curran, M.D.
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Recruiting
- Cincinnati Children's Hospital Medical Center
-
Contact:
- Jeremy Rubinstein, MD
- Email: Jeremy.Rubinstein@cchmc.org
-
Cincinnati, Ohio, United States, 45226
- Recruiting
- Oncology Hematology Care
-
Principal Investigator:
- Ahmed Galal, MD
-
Contact:
- Doug Hart
- Phone Number: 22401 513-751-2273
- Email: Doug.Hart@USOncology.com
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19390
- Recruiting
- Children's Hospital of Philadelphia
-
Contact:
- Brooke Leibfreid
- Email: leibfreidb@chop.edu
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- TriStar Bone Marrow Transplant / Sarah Cannon Transplant & Cellular Therapy
-
Contact:
- Email: SCRI.DDUreferrals@scri.com
-
Principal Investigator:
- Stephen Strickland, M.D.
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center
-
Principal Investigator:
- Elias Jabbour, M.D.
-
San Antonio, Texas, United States, 78229
- Recruiting
- Sarah Cannon Transplant and Cellular Therapy Methodist Hospital
-
Principal Investigator:
- Nosha Farhadfar, M.D.
-
Contact:
- Christian Herrera
- Phone Number: 210-575-6026
- Email: SCRI@Methodisttransplantinstitute.com
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
- Recruiting
- Sarah Cannon, Virginia Oncology Associates
-
Contact:
- Wendi Gobhardt
- Phone Number: 757-213-5813
- Email: Wendi.Gobhardt@usoncology.com
-
Principal Investigator:
- Gary L. Simmons, D.O.
-
-
Washington
-
Seattle, Washington, United States, 98105
- Recruiting
- Seattle Children's Hospital
-
Principal Investigator:
- Adam Lamble, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Disease Criteria: Evidence of T-ALL or T-LBL, as defined by World Health Organization (WHO) classification, and either relapse/refractory or MRD positive
- Age: Lower age limit of ≥ 6 months; adequate organ function
- Eastern Cooperative Oncology Group (ECOG) 0 or 1/Karnofsky Performance Status 70 and above at Screening.
Key Exclusion Criteria:
- Prior treatment with any anti-CD7 therapy.
- Patients with decompensated hemolytic anemia.
- Presence of Grade 2 to 4 acute or extensive chronic GvHD requiring systemic immunosuppression. Grade 1 GvHD not requiring immunosuppression or Grade 2 skin GvHD if treated with topical therapy only are acceptable.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: WU-CART-007
A CD7-directed chimeric antigen receptor (CAR) T-cell product. Lymphodepletion |
A single IV infusion of WU-CART-007 |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
R/R Cohort - Composite Complete Response Rate
Time Frame: 24 months
|
CRc is defined as proportion of patients that achieve a complete remission (CR) + CR with incomplete hematologic recovery (CRi) |
24 months
|
|
MRD Pos Cohort - Response Rate
Time Frame: 24 months
|
Defined as the efficacy of WU-CART-007 to induce complete MRD negative response |
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Cherry Thomas, MD, Allotera Therapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Immune System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Leukemia, Lymphoid
- Leukemia
- Hemic and Lymphatic Diseases
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Other Study ID Numbers
- WUC007-03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.